GNLD Science: On The World Stage In The New England Journal Of Medicine


75928D18-EA9B-4E7E-8DCE-0164FACF0086@localIn the world of Science, one of the highest levels of recognition you can achieve is to have your work published or cited in world-leading scientific journals. Throughout our history, research on GNLD products, by us and others, has been published in such prestigious journals as the American Journal of Clinical Nutrition, Journal of the American College of Nutrition, Annals of the New York Academy of Sciences, and several others. We have a lot to be proud of!

I’m happy to report that we have just attained our highest level yet for recognition of our scientific excellence—citation in the New England Journal of Medicine

In the May 19, 2011 edition of this most prestigious of scientific journals, in an editorial article titled Clinical Implications of Basic Research: Fatty Acids and Retinopathy (1), Dr. Emily Chew (MD) from the US National Institute of Health reviewed the mechanism by which omega-3 fatty acids protect from age-related eye disease (age-related macular degeneration, retinopathy and diabetic retinopathy). She concluded that taking an omega-3 supplement to prevent the disease or slow its rate of progression may prove a better course of action than the current, often painful therapies. As evidence for this, she cited an article in the February 09, 2011 edition of Science Translational Medicine (2) co-authored by SAB member Dr. Arianna Carughi, in which the human clinical evidence component was drawn in part from our 2009 clinical trial on Salmon Oil Plus.

For decades, GNLD has been committed to doing great science for the purpose of delivering great products. That long commitment has allowed us to develop relationships with many of the world’s top researchers and opened doors for opportunity to participate at the very leading edge of science. This latest achievement that connects research on our product Salmon Oil Plus with The New England Journal of Medicine is further testament that the pillar of our GNLD Difference, “Backed by Science”, is alive and well—and thriving!

John R. Miller
SAB Member




  1. New England Journal of Medicine, 364;20, “Fatty Acids in Retinopathy”, pages 1970-1971, May 19, 2011
  2. Science Translational Medicine, Vol. 3, Issue 69, Pages 1-12: “5-Lipoxygenase Metabolite 4-HDHA Is a Mediator of the Antiangiogenic Effect of w-3 Polyunsaturated Fatty Acids.” February 09, 2011 Click here to view (PDF)

 

 

salmon oil plus